DDInter1642 DDInter38
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Interferon alfa-n1
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Aldesleukin may lead to a major life threatening interaction when taken with Rotavirus vaccine
Aldesleukin may lead to a major life threatening interaction when taken with Interferon alfa-n1